Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
Kenvue
KVUE
|
+$344M |
| 2 |
JPMorgan Chase
JPM
|
+$161M |
| 3 |
Extra Space Storage
EXR
|
+$134M |
| 4 |
GE HealthCare
GEHC
|
+$113M |
| 5 |
Ferguson
FERG
|
+$97.1M |
Top Sells
| 1 |
PDCE
PDC Energy, Inc.
PDCE
|
+$313M |
| 2 |
Super Micro Computer
SMCI
|
+$305M |
| 3 |
UNVR
Univar Solutions Inc.
UNVR
|
+$176M |
| 4 |
LSI
Life Storage, Inc.
LSI
|
+$160M |
| 5 |
Walmart
WMT
|
+$112M |
Sector Composition
| 1 | Technology | 17.36% |
| 2 | Financials | 16.12% |
| 3 | Industrials | 12.99% |
| 4 | Consumer Discretionary | 10.82% |
| 5 | Healthcare | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATYR
3101
aTyr Pharma
ATYR
$521M
| $374K | ﹤0.01% |
236,449
-41,355
| -15% | -$65.3K |
|
3102
Erasca
ERAS
$448M
| $373K | ﹤0.01% |
189,565
+146,193
| +337% | +$288K |
|
3103
Air T
AIRT
$67.8M
| $372K | ﹤0.01% |
16,623
| – | – |
|
3104
CF Bankshares
CFBK
$162M
| $371K | ﹤0.01% |
21,939
| – | – |
|
|
IMA
3105
ImageneBio, Inc. Common Stock
IMA
$98.6M
| $371K | ﹤0.01% |
7,135
+2,209
| +45% | +$115K |
|
3106
Champions Oncology
CSBR
$88.9M
| $367K | ﹤0.01% |
59,080
-28,591
| -33% | -$178K |
|
3107
Bank First Corp
BFC
$1.26B
| $366K | ﹤0.01% |
4,747
+668
| +16% | +$51.5K |
|
3108
Telus
TU
$24.1B
| $364K | ﹤0.01% |
22,265
-5
| -0% | -$82 |
|
3109
United Bancorp
UBCP
$84.8M
| $356K | ﹤0.01% |
30,801
| – | – |
|
3110
CPI Card Group
PMTS
$165M
| $356K | ﹤0.01% |
19,208
-13,130
| -41% | -$243K |
|
|
WMPN
3111
DELISTED
William Penn Bancorporation Common Stock
WMPN
| $352K | ﹤0.01% |
28,185
+4
| +0% | +$50 |
|
3112
Nektar Therapeutics
NKTR
$911M
| $350K | ﹤0.01% |
39,199
-14,738
| -27% | -$132K |
|
3113
Arq
ARQ
$299M
| $350K | ﹤0.01% |
196,440
-108,050
| -35% | -$192K |
|
3114
Energy Services of America
ESOA
$173M
| $348K | ﹤0.01% |
86,038
+30,243
| +54% | +$122K |
|
3115
C4 Therapeutics
CCCC
$189M
| $340K | ﹤0.01% |
182,625
-80,759
| -31% | -$150K |
|
3116
Lexicon Pharmaceuticals
LXRX
$396M
| $339K | ﹤0.01% |
310,815
-432,922
| -58% | -$472K |
|
3117
Liquidia Corp
LQDA
$2.38B
| $337K | ﹤0.01% |
53,103
-3,623
| -6% | -$23K |
|
|
IGMS
3118
DELISTED
IGM Biosciences
IGMS
| $335K | ﹤0.01% |
40,173
-12,080
| -23% | -$101K |
|
3119
MediciNova
MNOV
$62.8M
| $330K | ﹤0.01% |
157,942
+43,169
| +38% | +$90.2K |
|
3120
Alpha Pro Tech
APT
$51.3M
| $329K | ﹤0.01% |
75,911
| – | – |
|
|
TGB
3121
Taseko Mines
TGB
$1.08B
| $329K | ﹤0.01% |
258,967
-34,879
| -12% | -$44.3K |
|
|
FSR
3122
DELISTED
Fisker Inc.
FSR
| $328K | ﹤0.01% |
51,082
| – | – |
|
3123
Comscore
SCOR
$31.8M
| $327K | ﹤0.01% |
26,606
-12,321
| -32% | -$151K |
|
3124
Sight Sciences
SGHT
$182M
| $326K | ﹤0.01% |
96,811
-63,754
| -40% | -$215K |
|
3125
Atara Biotherapeutics
ATRA
$83.2M
| $325K | ﹤0.01% |
8,778
-17,453
| -67% | -$646K |
|